5 news items
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
12 Jun 24
administered through Cycle 8, there were 17 Grade 1, 3 Grade 2, and 1 Grade 3 adverse events ("AEs") related to investigational product ("IP"). The Grade 3 AE
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGN
23 May 24
to investigational product (IP). The Grade 3 AE of increased fatigue resolved after 1 day with no intervention required
NKGen Biotech Announces FDA Clearance Of IND Application For SNK01 NK Cell Therapy in Parkinson's Disease
NKGN
29 Apr 24
natural killer ("NK") cell therapeutics, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data In Alzheimer's Disease At The Tau2024 Global Conference
NKGN
25 Mar 24
, and CAR-NK Natural Killer ("NK") cell therapeutics, today presented additional Phase 1 clinical trial data on the use of its investigational
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference
NKGN
25 Mar 24
-NK Natural Killer ("NK") cell therapeutics, today presented additional Phase 1 clinical trial data on the use of its investigational autologous NK
- Prev
- 1
- Next